Tela Bio, INC

TELA Bio, Inc. announces the immediate departure of CEO Antony Koblish and the appointment of Heather Getz as the new Chief Executive Officer and a director.

TELA Bio's stockholders approved an amendment to its 2019 Equity Incentive Plan, increasing the authorized shares by 3.5 million.

TELA Bio announced preliminary Q1 2026 revenue of $19 million and a significant restructuring of its Board of Directors.

TELA Bio, Inc. announced strong fourth quarter and full year 2025 financial results, driven by increased revenue and strategic operational improvements, alongside a new credit facility.

TELA Bio, Inc. received a Nasdaq deficiency letter for failing to maintain a minimum $1.00 bid price, initiating a 180-day compliance period.

TELA Bio, Inc. announced a new $70 million senior secured term loan facility and a registered direct offering expected to yield $11.9 million in net proceeds, while terminating its prior credit agreement with MidCap Financial Trust.

TELA Bio, Inc. announced its third-quarter 2025 results, reporting a 9% revenue increase to $20.7 million and a 17% reduction in net loss, alongside a new $70 million credit facility and a $13 million direct offering.

TELA Bio, Inc. announced significant revenue growth and a narrower net loss for the second quarter of 2025, driven by new customer additions and product launches, despite continued overall losses.

TELA Bio's first quarter 2025 revenue increased by 12% year-over-year, but the company's net loss also significantly increased due to various factors including the absence of a gain from the sale of a product line that occurred in the prior year.

TELA Bio's Q3 2024 results show a 26% increase in revenue year-over-year, alongside a reduced net loss and the implementation of cost-cutting measures.

TELA Bio's Q2 2024 results show a revenue increase driven by higher unit sales, alongside a strategic sale of a product line, impacting overall profitability.

TELA Bio's first quarter 2024 results show a significant revenue increase of 39% year-over-year, driven by higher unit sales of both OviTex and OviTex PRS products.

TELA Bio, a medical technology company, reported a 16% increase in revenue to $80.3 million for 2025, alongside a net loss of $38.8 million, as it expands its soft-tissue reconstruction product portfolio.

TELA Bio, Inc. announces a 19% increase in revenue for 2024, driven by growth in OviTex and OviTex PRS product sales, while reducing its net loss by 19%.

TELA Bio, Inc. reports a significant 41% revenue increase in its 2023 annual filing, driven by strong sales of its OviTex and OviTex PRS products.

William J. Plovanic, a Director of TELA Bio, Inc., received 20,930 shares of common stock on July 15, 2026.

Joseph H Capper, a Director of TELA Bio, Inc., received 6,227 shares of common stock on July 15, 2026.

Director Betty Jo Rocchio acquired 11,675 restricted stock units and 17,335 stock options as part of annual equity compensation.

Director Joseph Capper was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.

Director William J. Plovanic acquired 11,675 restricted stock units and 17,335 stock options as part of an annual equity grant.

Director Guido Neels was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.

TELA Bio, Inc. announces its 2026 Annual Meeting of Stockholders, featuring a significant board refreshment and a proposal to increase equity incentive plan shares.

TELA Bio, Inc. will hold its annual stockholder meeting virtually on May 28, 2025, and proxy materials are now available online.

TELA Bio, Inc. is holding its 2025 Annual Meeting of Stockholders virtually on May 28, 2025, to vote on several key proposals, including the election of directors, ratification of the independent auditor, executive compensation, and amendments to the equity incentive plan and corporate charter.

TELA Bio, Inc. will hold its annual stockholder meeting virtually on June 4, 2024, and proxy materials are now available online.

TELA Bio, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 4, 2024, featuring proposals for director elections and auditor ratification.

EW Healthcare Partners filed a Schedule 13D reporting the appointment of an affiliated operating partner to the TELA Bio, Inc. Board of Directors.

Laurence W. Lytton has disclosed beneficial ownership of 2,442,341 shares, representing 5.5% of the outstanding common stock of TELA Bio, Inc., as of March 31, 2026.

EW Healthcare Partners and its affiliates have increased their beneficial ownership in TELA Bio, Inc. to an aggregate of 17.32% of common stock following a recent direct offering.

Laurence W. Lytton has reported a 7.2% beneficial ownership stake in TELA Bio, Inc., holding 2,865,305 shares of common stock as of September 30, 2025.

GROW Funds, LLC has filed an amendment to its Schedule 13G, indicating its beneficial ownership in TELA Bio, Inc. common shares has fallen to 5% or less.

Laurence W. Lytton has increased his beneficial ownership in TELA Bio, Inc. to 8.5% of the common stock outstanding.

A group of investment entities and individuals, led by North Run Capital, LP, has filed an amended Schedule 13G disclosing a collective beneficial ownership of 9.3% of TELA Bio, Inc.'s common stock.